Orchestra BioMed Holdings, Inc. (OBIO)
(Real Time Quote from BATS)
$2.67 USD
0.00 (0.00%)
Updated Aug 6, 2025 03:44 PM ET
After-Market: $2.64 -0.03 (-1.12%) 4:08 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OBIO 2.67 0.00(0.00%)
Will OBIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OBIO
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates
OBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates
Other News for OBIO
Orchestra BioMed secures over $111M in proceeds, committed capital
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following ...
12 Health Care Stocks Moving In Friday's Intraday Session
Orchestra BioMed (OBIO) Sets Public Offering at $2.75 Per Share
Orchestra BioMed announces pricing of $40 million public offering